ONCE-MONTHLY RIFAMPICIN PLUS DAILY DAPSONE IN INITIAL TREATMENT OF LEPROMATOUS LEPROSY

@article{Yawalkar1982ONCEMONTHLYRP,
  title={ONCE-MONTHLY RIFAMPICIN PLUS DAILY DAPSONE IN INITIAL TREATMENT OF LEPROMATOUS LEPROSY},
  author={S. J. Yawalkar and A. C. Mcdougall and J. Languillon and S S Ghosh and S K Hajra and Diltor Vladimir Ara{\'u}jo Opromolla and Claudio Joaquim Sampaio Tonello},
  journal={The Lancet},
  year={1982},
  volume={319},
  pages={1199-1202}
}
Treatment of leprosy
TLDR
Testing for recent nerve damage and treating it with steroids is essential and Dermatologists already have an important role in treating patients in the large Indian and Brazilian cities, and this is likely to increase as leprosy programmes are integrated into primary care.
NEW DEVELOPMENT IN LEPROSY CONTROL AND THE ISSUES OF INTEGRATION
TLDR
It is suggested that integration with the TB seroices might be possible about three years after the setting-up of multidrug therapy in any area, and full integration into PHC could be possible after about 10 years.
Uniform multidrug therapy for leprosy patients in Brazil (U-MDT/CT-BR): Results of an open label, randomized and controlled clinical trial, among multibacillary patients
TLDR
The hypothesis that UMDT is an acceptable option to be adopted in endemic countries to treat leprosy patients in the field worldwide is supported.
Considerations in the design of clinical trials for multibacillary leprosy treatment
In 1991, the World Health Assembly adopted a resolution to attain the goal of global elimination of leprosy as a public health problem by the year 2000, based on universal access to multidrug therapy
An enhanced regimen as post-exposure chemoprophylaxis for leprosy: PEP++
TLDR
The Netherlands Leprosy Relief (NLR) is developing a multi-country study aiming to show that breaking the chain of transmission of M. leprae is possible, evidenced by a dramatic reduction in incidence.
Considerations on clinical trials of leprosy treatment: need of novel drug combinations
TLDR
To replace the standard WHO-MDT, the new combination must be the shortest, simplest and, consequently, most affordable treatment possible.
The management of leprosy
TLDR
An expert committee of the World Health Organization (WHO) has suggested combination chemotherapy in shorter courses to minimize the risk that resistance might develop.
The imperatives of leprosy treatment in the pre‐ and post‐global leprosy elimination era: Appraisal of changing the scenario to current status
TLDR
The progress made in the treatment of this neglected tropical disease from the time diaminodiphenylsulfone (dapsone) monotherapy was introduced in its management, to the rapidly changing situation following the advent of WHO‐recommended MDT and subsequently to short‐course newer drug regimens with the prime objective to eliminate/eradicate leprosy from the world.
Pharmacologic management of Mycobacterium ulcerans infection
TLDR
Pharmacological treatment of Buruli ulcer (Mycobacterium ulcerans infection; BU) is highly effective, as shown in two randomized trials in Africa, and an array of repurposed tuberculosis and leprosy drugs appears effective in vitro and in animal models.
...
...

References

SHOWING 1-10 OF 15 REFERENCES
Experimental and Clinical Studies on Rifampicin in Treatment of Leprosy
TLDR
In a formal pilot-type trial on six previously untreated patients with active lepromatous leprosy, rifampicin was as effective as standard treatment with dapsone, and Myco.
Rifampicin for lepromatous leprosy: nine years' experience.
TLDR
Although rifampicin proved more effective than dapsone, it is unlikely that used by itself if can significantly shorten the length of treatment in lepromatous leprosy, and initial intensive combined treatment with two or more bactericidal drugs (including rifampsicin) warrants further investigation.
Drug interactions -- the influence of rifampicin and clofazimine on the urinary excretion of DDS.
TLDR
Observations on this aspect in 25 cases of lepromatous leprosy treated with a 15 day schedule of Rifampicin at a dose of 600 mg daily along with DDS are presented and the findings indicate that Clofazimine does not exert any influence on DDs excretion byLeprosy patients.
Effect of Rifampin, Clofazimine, and B1912 on the Viability of Mycobacterium leprae in Established Mouse Footpad Infection
  • I. Holmes, D. Banerjee, G. Hilson
  • Biology, Medicine
    Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine
  • 1976
Summary Continuous dietary administration of rifampin to mice with an established Mycobacterium leprae footpad infection reduced the bacillary solid ratio, with an estimated survival half-life of 5-6
The six disease of WHO.
  • M. Waters
  • Biology, Medicine
    British medical journal
  • 1981
Leprosy is the only bacterial disease included among the six selected for the United Nations Development Programme/ World Bank/World Health Organisation's special programme for research and training
Adverse reactions to rifampicin.
TLDR
The reactions covered comprise those to both daily and intermittent administration, namely cutaneous and gastrointestinal reactions, hepatitis, and thrombocytopenic purpura, and those to intermittent administration only, namely "flu" syndrome, shock, shortness of breath, haemolytic anaemia, and renal failure.
A Handbook on Leprosy
  • W. Jopling
  • Medicine
    Bristol Medico-Chirurgical Journal (1883)
  • 1896
Definition, epidemiology and world distribution the disease the lepromin test diagnostic tests general principles of immunology and their application to the leprosy patient leprosy reactions
Long-term treatment of dapsone-resistant leprosy with rifampicin: clinical and bacteriological studies.
...
...